|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||56.73 - 57.53|
|52 Week Range||46.01 - 60.45|
|PE Ratio (TTM)||19.72|
|Dividend & Yield||1.56 (2.71%)|
|1y Target Est||N/A|
Despite all the takeover rumors and blockbuster drug sales, it’s been a disappointing year for Bristol-Myers Squibb. Shares of the drugmaker, down 2.5% this year, haven’t recovered from the drubbing they took last year when its key cancer drug Opdivo failed in a big lung cancer study. Late Tuesday, the woes continued when Bristol-Myers (BMY) delivered mixed results from a late-stage study testing Opdivo and an older drug, Yervoy, for patients newly diagnosed with advanced or metastatic kidney cancer.
Credit Suisse termed the market reaction to Bristol-Myers Squibb Co (NYSE: BMY )'s CM-214 data as overly pessimistic. The comment was based on the 3-percent pullback in the company's shares in after-hours ...
Despite a Phase 3 stumble, BMY stock is holding up.